Sell Patent Free Capecitabine Supply

Enlarge

Member Type:
Post Date: Apr 24, 2008
Validity Date: Mar 3, 2018
Category: Chemicals » Pharmaceutical Chemicals

» Recommend » Report Fraud

Description

Product Name：capecitabine

CAS#：154361-50-9

Molecular Weight：359.35

Chemical Formula：C15H22FN3O6

Appearance：White or off-White Crystalline Powder

Ref. Standard: Enterprise

Assay By HPLC : >95.00%

Description:

Our Capecitabine is totally patent free product which is using own technology. It can be produced and saled among the world legally by our customers.

Capecitabine is a recently developed drug. It is a type of medicine called an antimetabolite because it interferes with the metabolism and growth of cells. Capecitabine is an unusual anti-cancer drug in that it is most active in cancer cells; normal cells are exposed to far lower concentrations of the drug. Cancer cells convert capecitabine into another anti-cancer drug called 5-fluorouracil (fluorouracil). This substance prevents cells from growing and reproducing by interfering with the production of DNA and RNA. Eventually the cells die. because it interferes with the and growth of cells. Capecitabine is an unusual anti-cancer drug in that it is most active in cancer cells; normal cells are exposed to far lower concentrations of the drug. Cancer cells convert capecitabine into another anti-cancer drug called 5-fluorouracil (). This substance prevents cells from growing and by interfering with the production of DNA and RNA. Eventually the cells die.

Capecitabine has been approved by the U.S. Food and Drug Administration for the treatment of metastasized breast cancer that is resistant to standard chemotherapy. Capecitabine may be used in combination with the drug docetaxel (Taxotere). A study completed in 2003 found that the combination of docetaxel and capecitabine improves survival in women with metastatic breast cancer without a significant increase in treatment-related side effects.. Capecitabine may be used in combination with the drug (Taxotere). A study completed in 2003 found that the combination of and capecitabine improves survival in women with metastatic breast cancer without a significant increase in treatment-related side effects.

A study completed in 2001 found that capecitabine is as effective as 5-fluorouracil for treating metastasized colorectal cancer, and has fewer, and has fewer and less severe side effects. However, it does not increase the average survival time of approximately 13 months.